Abstract
ACE2 has long been known as an injury protective protein, which can protect against a variety of organ damage such as the heart, liver, kidney, and lung. Especially in cardiovascular diseases, as a negative regulator of RAAS, ACE2 is an extremely important protective factor that mainly plays a role by converting Ang II to Ang-(1-7). Nevertheless, with the recent outbreak of COVID-19, it is exposed that another identity of ACE2 is the entry receptor for SARS-CoV-2, which previously serves as the entry receptor for SARS. With the in-depth clinical research, it is found that the severity and susceptibility of COVID-19 are related to cardiovascular diseases, and SARS-CoV-2 binding to ACE2 receptor is also potentially associated with heart injury symptoms. Therefore, in this article, we mainly summarize the relationship between ACE2, COVID-19, and cardiovascular diseases/heart injury.
Keywords: COVID-19, cardiovascular diseases, heart injury, SARS-CoV-2, ACE2, RAAS.
Current Drug Targets
Title:ACE2 as a Key Target for Treatment of COVID-19 Related Cardiovascular Diseases: Current Progress and Prospect
Volume: 22 Issue: 16
Author(s): Shuainan Li, Wenya Ma, Fan Yang, Yan Xu, Binbin Xu and Benzhi Cai*
Affiliation:
- Department of Pharmacy at the Second Affiliated Hospital, and Department of Pharmacology (The Key Laboratory of Cardiovascular Research, Ministry of Education) at College of Pharmacy, Harbin Medical University, Harbin,China
Keywords: COVID-19, cardiovascular diseases, heart injury, SARS-CoV-2, ACE2, RAAS.
Abstract: ACE2 has long been known as an injury protective protein, which can protect against a variety of organ damage such as the heart, liver, kidney, and lung. Especially in cardiovascular diseases, as a negative regulator of RAAS, ACE2 is an extremely important protective factor that mainly plays a role by converting Ang II to Ang-(1-7). Nevertheless, with the recent outbreak of COVID-19, it is exposed that another identity of ACE2 is the entry receptor for SARS-CoV-2, which previously serves as the entry receptor for SARS. With the in-depth clinical research, it is found that the severity and susceptibility of COVID-19 are related to cardiovascular diseases, and SARS-CoV-2 binding to ACE2 receptor is also potentially associated with heart injury symptoms. Therefore, in this article, we mainly summarize the relationship between ACE2, COVID-19, and cardiovascular diseases/heart injury.
Export Options
About this article
Cite this article as:
Li Shuainan , Ma Wenya , Yang Fan , Xu Yan , Xu Binbin and Cai Benzhi *, ACE2 as a Key Target for Treatment of COVID-19 Related Cardiovascular Diseases: Current Progress and Prospect, Current Drug Targets 2021; 22 (16) . https://dx.doi.org/10.2174/1389450122666210319110320
DOI https://dx.doi.org/10.2174/1389450122666210319110320 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HIV-1 Proteins, Tat and gp120, Target the Developing Dopamine System
Current HIV Research Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets Dynamic Ventricular Repolarisation: From Physiology to Prognosis
Current Cardiology Reviews Antithrombotic Treatment after Atrial Fibrillation Ablation
Current Pharmaceutical Design Folic Acid Can Contribute to Memory Deficit and Na+, K+- ATPase Failure in the Hippocampus of Adolescent Rats Submitted to Hypoxia- Ischemia
CNS & Neurological Disorders - Drug Targets Clinical Thiazolidinediones as PPARγ Ligands with the Potential for the Prevention of Cardiovascular Disease in Diabetes
Current Diabetes Reviews Congenital Heart Disease: The Crossroads of Genetics, Epigenetics and Environment
Current Genomics 4-Hydroxynonenal in the Pathogenesis and Progression of Human Diseases
Current Medicinal Chemistry Interaction of the Heart and Lungs During Exercise: Physiology and Pathophysiology in Children with Congenital Heart Disease
Current Respiratory Medicine Reviews Role of Copper in Angiogenesis and Its Medicinal Implications
Current Medicinal Chemistry Treatment of Takotsubo Cardiomyopathy
Current Pharmaceutical Design Subject Index To Volume 2
Current Hypertension Reviews Interatrial Block in the Modern Era
Current Cardiology Reviews A Review on Novel Ligand Targeted Delivery for Cardiovascular Disorder
Current Drug Delivery Clopidogrel, Aspirin and Proton Pump Inhibition after Percutaneous Valve Implants: An Update
Current Pharmaceutical Design Teratological Consequences of Nitric Oxide Synthesis Inhibition
Current Pharmaceutical Design Renoprotection and Mechanisms of Erythropoietin and Its Derivatives Helix B Surface Peptide in Kidney Injuries
Current Protein & Peptide Science Heart Rate as a Therapeutic Target in Angina Pectoris
Current Pharmaceutical Design Exercise and Ischemic Preconditioning
Current Cardiology Reviews Protective Effects of TRPV1 Activation Against Cardiac Ischemia/ Reperfusion Injury is Blunted by Diet-Induced Obesity
Cardiovascular & Hematological Disorders-Drug Targets